文献速递急性肾损伤慢性肾脏病水电解质与酸碱

双重RAAS抑制与糖尿病肾病患者急性肾损伤及高钾血症风险的相关性:系统综述与Meta分析

The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

该系统综述与Meta分析纳入31项随机对照试验共33048例糖尿病肾病患者,评估双重RAAS阻断与急性肾损伤及高钾血症风险。结果显示ACEi+ARB增加AKI和高钾血症风险,非甾体MRA+ACEi/ARB不增加AKI风险但高钾血症风险约2倍,甾体MRA+ACEi/ARB高钾血症风险约5倍。

要点

  • ACEi+ARB较单药治疗增加AKI风险(汇总RR 1.48,95%CI 1.23-1.39)和高钾血症风险(汇总RR 1.97,95%CI 1.32-2.94)。
  • 非甾体MRA+ACEi/ARB不增加AKI风险(汇总RR 0.97,95%CI 0.81-1.16),但高钾血症风险约2倍(汇总RR 2.05,95%CI 1.84-2.28)。
  • 甾体MRA+ACEi/ARB高钾血症风险约5倍(汇总RR 5.42,95%CI 2.15-13.67)。

核心结论

  • 与RAASi单药治疗相比,RAASi双重治疗与AKI和高钾血症风险增加相关。
  • RAAS抑制剂与非甾体MRA双重治疗不增加AKI风险,但高钾血症风险相似,且低于RAAS抑制剂与甾体MRA的双重治疗。

研究设计与样本

  • 系统综述与Meta分析,纳入2006年1月1日至2022年5月30日发表的随机对照试验。
  • 研究人群为接受双重RAAS阻断的成人糖尿病肾病患者,共纳入31项随机对照试验、33048例患者。
  • 采用随机效应模型计算汇总风险比(RR)及95%置信区间(CI)。

主要发现

  • ACEi+ARB组2690例患者中发生208例AKI事件,ACEi或ARB单药治疗组4264例患者中发生170例(汇总RR 1.48,95%CI 1.23-1.39)。
  • ACEi+ARB组2818例患者中发生304例高钾血症事件,ACEi或ARB单药治疗组4396例患者中发生208例(汇总RR 1.97,95%CI 1.32-2.94)。
  • 非甾体MRA+ACEi或ARB组与ACEi或ARB单药治疗相比,AKI风险未增加(汇总RR 0.97,95%CI 0.81-1.16)。
  • 非甾体MRA+ACEi或ARB组7837例患者中发生953例高钾血症事件,单药治疗组6895例患者中发生454例(汇总RR 2.05,95%CI 1.84-2.28)。
  • 甾体MRA+ACEi或ARB组245例高危患者中发生28例高钾血症事件,单药治疗组248例高危患者中发生5例(汇总RR 5.42,95%CI 2.15-13.67)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Dual renin-angiotensin-aldosterone system (RAAS) blockade involves dual therapy with a combination of angiotensin-converting enzyme inhibitors (ACEis), angiotensin-receptor blockers (ARBs), direct renin inhibitors (DRIs), or mineralocorticoid receptor antagonists (MRAs). It is hypothesized that dual RAAS blockade would result in a more complete inhibition of the RAAS cascade. However, large clinical trials on dual RAAS inhibition have shown increased risk of acute kidney injury (AKI) and hyperkalemia without additional benefit on mortality, cardiovascular events, or chronic kidney disease (CKD) progression compared to RAAS inhibitor monotherapy in patients with diabetic kidney disease (DKD). The development of newer, more selective non-steroidal MRAs as cardiorenal protective therapies has created a new opportunity for dual RAAS inhibition. We conducted a systematic review and meta-analysis of the risks of AKI and hyperkalemia with dual RAAS blockade in patients with DKD. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: This is a systematic review and meta-analysis of the randomized controlled trials (RCT) published from 1 January 2006 to 30 May 2022. The study population included adult patients with DKD receiving dual RAAS blockade. A total of 31 RCTs and 33 048 patients were included in the systematic review. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using random effects. RESULTS: There were 208 AKI events in 2690 patients on ACEi + ARB versus 170 in 4264 patients with ACEi or ARB monotherapy (pooled RR 1.48, 95% CI: 1.23-1.39). There were 304 hyperkalemia events in 2818 patients on ACEi + ARB versus 208 in 4396 patients with ACEi or ARB monotherapy (pooled RR 1.97, 95% CI: 1.32-2.94). A non-steroidal MRA + ACEi or ARB showed no increase in the risk of AKI (pooled RR 0.97, 95% CI: 0.81-1.16) compared to ACEi or ARB monotherapy but had a 2-fold higher risk of hyperkalemia with 953 events in 7837 patients in dual therapy versus 454 events in 6895 patients in monotherapy (pooled RR 2.05, 95% CI: 1.84-2.28). A steroidal MRA + ACEi or ARB had a 5-fold higher risk of hyperkalemia with 28 events in 245 at risk in dual therapy versus five events in 248 at risk in monotherapy (pooled RR 5.42 95% CI: 2.15-13.67). CONCLUSION: Dual therapy with RAASi is associated with an increased risk of AKI and hyperkalemia compared to RAASi monotherapy. Conversely, dual therapy with RAAS inhibitors and non-steroidal MRAs have no additional risk of AKI but a similar risk of hyperkalemia, which is lower than dual therapy with RAAS inhibitors and steroidal MRAs.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Whitlock R, Leon SJ, Manacsa H, et al. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2023. PMID: 37309038. doi:10.1093/ndt/gfad101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。